title: Paroxetine: a new serotonin reuptake inhibitor for the treatment of depression.
abstract: The introduction of the selective serotonin reuptake inhibitors (SSRIs) over the past several years has made a major impact on the treatment of depression and other neuropsychiatric disorders. Agents in this heterogeneous group of compounds are generally better tolerated and less toxic than the tricyclic antidepressants (TCAs), which they have in many respects superseded. This review summarizes available data on paroxetine, the newest SSRI to receive approval for the treatment of depression.
authors.affiliation: Clinical Neuroscience Research Unit, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven.
authors.forename: T L
authors.initials: TL
authors.lastname: Sherman
authors.forename: C J
authors.initials: CJ
authors.lastname: McDougle
authors.forename: L H
authors.initials: LH
authors.lastname: Price
mesh_terms: D003866:Depressive Disorder / Q000188:drug therapy*; D004347:Drug Interactions; D006801:Humans; D017374:Paroxetine / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D017374:Paroxetine